Recombinant human endostatin - Simcere

Drug Profile

Recombinant human endostatin - Simcere

Alternative Names: Endostar; Endu; rh-endostatin; YH-16

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Simcere Pharmaceutical Group
  • Developer Peking University; Simcere Pharmaceutical Group
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Brain metastases; Colorectal cancer; Gastric cancer; Malignant ascites; Malignant melanoma; Malignant pleural effusion; Oesophageal cancer; Osteosarcoma; Small cell lung cancer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Late-stage disease) in China (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable) in China (SC) (NCT02652234)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top